JP2009529041A - 骨粗鬆症治療のためのｇｓｋ−３阻害薬 - Google Patents

骨粗鬆症治療のためのｇｓｋ−３阻害薬 Download PDF

Info

Publication number
JP2009529041A
JP2009529041A JP2008558230A JP2008558230A JP2009529041A JP 2009529041 A JP2009529041 A JP 2009529041A JP 2008558230 A JP2008558230 A JP 2008558230A JP 2008558230 A JP2008558230 A JP 2008558230A JP 2009529041 A JP2009529041 A JP 2009529041A
Authority
JP
Japan
Prior art keywords
pyridin
carboxamide
amino
methylpiperazin
pyrazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008558230A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009529041A5 (enExample
Inventor
アンナ−レーナ・ベルイ
ラータン・バート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38475142&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2009529041(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2009529041A publication Critical patent/JP2009529041A/ja
Publication of JP2009529041A5 publication Critical patent/JP2009529041A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2008558230A 2006-03-08 2007-03-06 骨粗鬆症治療のためのｇｓｋ−３阻害薬 Pending JP2009529041A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78025206P 2006-03-08 2006-03-08
PCT/SE2007/000216 WO2007102770A1 (en) 2006-03-08 2007-03-06 Gsk-3 inhibitors for the treatment of osteoporosis

Publications (2)

Publication Number Publication Date
JP2009529041A true JP2009529041A (ja) 2009-08-13
JP2009529041A5 JP2009529041A5 (enExample) 2010-04-22

Family

ID=38475142

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008558230A Pending JP2009529041A (ja) 2006-03-08 2007-03-06 骨粗鬆症治療のためのｇｓｋ−３阻害薬

Country Status (16)

Country Link
US (1) US7576093B2 (enExample)
EP (1) EP1993550A4 (enExample)
JP (1) JP2009529041A (enExample)
KR (1) KR20080114717A (enExample)
CN (1) CN101394851A (enExample)
AR (1) AR059754A1 (enExample)
AU (1) AU2007222199A1 (enExample)
BR (1) BRPI0708619A2 (enExample)
CA (1) CA2644751A1 (enExample)
IL (1) IL193484A0 (enExample)
MX (1) MX2008011417A (enExample)
NO (1) NO20084182L (enExample)
TW (1) TW200800203A (enExample)
UY (1) UY30192A1 (enExample)
WO (1) WO2007102770A1 (enExample)
ZA (1) ZA200807234B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013517321A (ja) * 2010-01-19 2013-05-16 アストラゼネカ アクチボラグ ピラジン誘導体
JP2014518884A (ja) * 2011-05-23 2014-08-07 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリジン−及びピラジン誘導体

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100137330A1 (en) * 2007-03-08 2010-06-03 Ratan Bhat Use
KR101712576B1 (ko) 2008-11-10 2017-03-06 버텍스 파마슈티칼스 인코포레이티드 Ａｔｒ 키나제의 억제제로서 유용한 화합물
PL3354650T3 (pl) 2008-12-19 2022-06-13 Vertex Pharmaceuticals Incorporated Związki przydatne jako inhibitory kinazy atr
US8962631B2 (en) 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9096584B2 (en) 2010-05-12 2015-08-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JP5836367B2 (ja) 2010-05-12 2015-12-24 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼ阻害剤として有用な化合物
WO2011143423A2 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP2013526540A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
JP2013526538A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
JP2013529643A (ja) 2010-06-23 2013-07-22 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用なピロロピラジン誘導体
CA2832100A1 (en) 2011-04-05 2012-10-11 Vertex Pharmaceuticals Incorporated Aminopyrazine compounds useful as inhibitors of tra kinase
JP2014522818A (ja) 2011-06-22 2014-09-08 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
WO2012178125A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2012178123A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
IN2014KN00943A (enExample) 2011-09-30 2015-08-21 Vertex Pharma
US8765751B2 (en) 2011-09-30 2014-07-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8853217B2 (en) 2011-09-30 2014-10-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
RU2018147217A (ru) 2011-09-30 2019-01-18 Вертекс Фармасьютикалз Инкорпорейтед Способы получения соединений, которые можно использовать в качестве ингибиторов киназы atr
AU2012315384B2 (en) 2011-09-30 2017-08-10 Vertex Pharmaceuticals Incorporated Treating pancreatic cancer and non-small cell lung cancer with ATR inhibitors
EP2776421A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8841450B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2013071090A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8841449B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2776429A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN104582795B (zh) 2012-04-05 2018-04-20 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物及其组合疗法
DK2904406T3 (en) 2012-10-04 2018-06-18 Vertex Pharma METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
US8912198B2 (en) 2012-10-16 2014-12-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
LT3418281T (lt) 2012-12-07 2021-01-11 Vertex Pharmaceuticals Inc. Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui
BR112015023261A2 (pt) 2013-03-14 2017-07-18 Massachusetts Inst Technology composições e métodos para expansão e cultura de células-tronco epiteliais
WO2014143240A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
HUE046727T2 (hu) 2013-12-06 2020-03-30 Vertex Pharma Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai
CN103804312B (zh) * 2014-02-17 2016-04-20 四川百利药业有限责任公司 一类氮杂环化合物及其制备方法和用途
ES2777608T3 (es) 2014-06-05 2020-08-05 Vertex Pharma Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útiles como inhibidores de ATR cinasa, la preparación de dicho compuesto y diferentes formas sólidas del mismo
US11179394B2 (en) 2014-06-17 2021-11-23 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of Chk1 and ATR inhibitors
CN107073042A (zh) 2014-09-03 2017-08-18 布里格海姆妇女医院公司 用于产生内耳毛细胞来治疗听力损失的组合物、系统和方法
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
CA3010610A1 (en) 2016-01-08 2017-07-13 The Brigham And Women's Hospital, Inc. Production of differentiated enteroendocrine cells and insulin producing cells
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
AU2017386417B2 (en) 2016-12-30 2022-07-14 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
WO2020037323A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating jag-1
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
WO2020163812A1 (en) 2019-02-08 2020-08-13 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
WO2025019346A2 (en) * 2023-07-14 2025-01-23 Celator Pharmaceuticals, Inc. Methods of use of a liposomal composition comprising an atr inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005505515A (ja) * 2001-07-05 2005-02-24 アストラゼネカ・アクチエボラーグ Ｇｓｋ−３に関連する病態の治療のためのアリールアミン
WO2005027883A1 (en) * 2003-09-19 2005-03-31 Proskelia Pharmaceuticals Gsk-3 beta inhibitors in the treatment of bone-related diseases
WO2005039485A2 (en) * 2003-08-13 2005-05-06 Chiron Corporation Gsk-3 inhibitors and uses thereof
JP2005519056A (ja) * 2002-01-10 2005-06-30 エフ．ホフマン−ラ　ロシュ　アーゲー 骨形成を増加させるための薬物の製造におけるＧＳＫ−３β阻害剤の使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4783532B2 (ja) 2000-02-05 2011-09-28 バーテックス ファーマシューティカルズ インコーポレイテッド Ｅｒｋのインヒビターとして有用なピラゾール組成物
SE0102438D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
ES2276048T3 (es) 2002-03-05 2007-06-16 Eli Lilly And Company Derivados de purina como inhibidores de cinasa.
SE0203752D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
CA2526845A1 (en) * 2003-06-06 2005-03-31 Wyeth Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005505515A (ja) * 2001-07-05 2005-02-24 アストラゼネカ・アクチエボラーグ Ｇｓｋ−３に関連する病態の治療のためのアリールアミン
JP2005519056A (ja) * 2002-01-10 2005-06-30 エフ．ホフマン−ラ　ロシュ　アーゲー 骨形成を増加させるための薬物の製造におけるＧＳＫ−３β阻害剤の使用
WO2005039485A2 (en) * 2003-08-13 2005-05-06 Chiron Corporation Gsk-3 inhibitors and uses thereof
WO2005027883A1 (en) * 2003-09-19 2005-03-31 Proskelia Pharmaceuticals Gsk-3 beta inhibitors in the treatment of bone-related diseases

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013517321A (ja) * 2010-01-19 2013-05-16 アストラゼネカ アクチボラグ ピラジン誘導体
JP2014518884A (ja) * 2011-05-23 2014-08-07 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリジン−及びピラジン誘導体
JP2016196492A (ja) * 2011-05-23 2016-11-24 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ピリジン−及びピラジン誘導体
JP2018115201A (ja) * 2011-05-23 2018-07-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ピリジン−及びピラジン誘導体

Also Published As

Publication number Publication date
TW200800203A (en) 2008-01-01
EP1993550A4 (en) 2010-04-21
KR20080114717A (ko) 2008-12-31
WO2007102770A1 (en) 2007-09-13
AU2007222199A1 (en) 2007-09-13
ZA200807234B (en) 2009-09-30
US7576093B2 (en) 2009-08-18
US20070213322A1 (en) 2007-09-13
WO2007102770A8 (en) 2008-01-31
UY30192A1 (es) 2007-10-31
BRPI0708619A2 (pt) 2011-06-07
IL193484A0 (en) 2009-08-03
CN101394851A (zh) 2009-03-25
MX2008011417A (es) 2008-09-22
NO20084182L (no) 2008-12-05
EP1993550A1 (en) 2008-11-26
CA2644751A1 (en) 2007-09-13
AR059754A1 (es) 2008-04-30

Similar Documents

Publication Publication Date Title
US7576093B2 (en) Method of treatment of bone-related disorders or conditions
US8501690B2 (en) Use of selective estrogen receptor modulator for joint fusion and other repair or healing of connective tissue
Blaschke et al. Soft and hard tissue response to zirconium dioxide dental implants--a clinical study in man
Yang et al. Bone responses to simvastatin-loaded porous implant surfaces in an ovariectomized model.
BRPI0813639A2 (pt) implante de tecido ósseo compreendendo íons de lítio.
US20080108658A1 (en) Methods of promoting osteogenesis
KR101493437B1 (ko) 컨센서스 펩티드
US8852240B2 (en) Methods and compositions for fostering and preserving bone growth
CN1329495A (zh) 伊班卓酸盐在促进内假体骨整合中的应用
US20100137330A1 (en) Use
JP2010526064A (ja) 骨組織の成長の育成および保存のための方法および組成物
JP4657296B2 (ja) 骨折治療用薬学的組成物
Vuletić et al. Implant prosthodontic rehabilitation after surgical treatment for an oropharyngeal malignant tumour using tantalum dental implants
Schneppendahl et al. Recovery after hip fractures: influence of bipolar hemiarthroplasty on physical disability and social dependency in the elderly
Wang et al. Expression of XBP1s in fibroblasts is critical for TiAl6V4 particle‐induced RANKL expression and osteolysis
KR102195611B1 (ko) 글루코실세라마이드 합성효소 억제제를 유효성분으로 포함하는 골 재생용 약학적 조성물 및 이를 이용한 골 재생용 지지체
Golden Bisphosphonates in improving the osseointegration of dental implants
GHETIU THE MOLDOVAN MEDICAL JOURNAL
Bambuliak et al. EXPERIENCE IN APPLYING OSTEOPLASTIC MATERIALS CONTAINING MULTIPOTENT MESENCHYMAL STROMAL CELLS AND HYDROXYAPATITE IN PATIENTS BEFORE THE PROCEDURE OF DENTAL IMPLANT PLACEMENT
WO2004024083A2 (en) Methods of bone healing
CN118217295A (zh) 25-羟基胆固醇在制备骨质疏松和骨溶解症治疗药物中的应用
Abdulla On-demand autograft: a novel method of biomaterial-induced bone growth
EP3315146A1 (en) Bone bioactive composition and uses thereof
Gobbato Early bone healing around two different experimental implant surfaces. A histologic and histomorphometric study in rabbits
FH Jr et al. Effect of calcitonin on bone healing following titanium implant insertion

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100303

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100303

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120807

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130108